New classification system for NET G3 patients
Part of Cancer clinical trials.
This trial studies a new way to classify and predict outcomes for people with a specific type of neuroendocrine tumor (NET G3). It uses tumor tissue and past scans to better understand your cancer and guide treatment.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 years or older.
- You must have a confirmed diagnosis of a well-differentiated neuroendocrine tumor (NET) that is Grade 3.
- You must be able to provide tumor tissue (from a biopsy or surgery) for testing.
- If you had a lower-grade NET before, you must have had specific PET scans (Gallium-68 DOTATOC and FDG-PET) for that earlier tumor.
- You cannot have other active cancers (like advanced breast or prostate cancer, or blood cancers).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial looks at epigenomic markers in different types of neuroendocrine tumors and cancers to find better ways to diagnose and treat them. It may help if you have a neuroendocrine tumor or certain other gastrointestinal cancers that can be surgically removed or biopsied.
This trial studies whether specific blood “biomarkers” can help confirm a type of cancer called NEN (neuroendocrine neoplasm) and show whether treatment is working early. It may help doctors start or adjust treatment sooner, especially for cancers that are advanced or have spread.
This study looks at how tumor and patient factors affect treatment response in well-differentiated GEP-NENs (neuroendocrine tumors of the digestive system). It may help doctors understand which treatments work best for people like you.
This trial is studying well-differentiated high-grade neuroendocrine tumors that start in the thymus, lung, or pancreas. It compares these tumors to understand them better and find better treatments.
This is a registry study that collects medical information from adults with neuroendocrine tumors (NETs) that start in the digestive organs. It helps researchers understand these cancers better and may support future studies.
This study tests a new type of PET/CT scan that looks for a marker called DLL3 on neuroendocrine cancer cells. It aims to see if this scan finds tumors better than standard scans, which could help guide treatment.
Hear when a new Neuroendocrine Neoplasm trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.